Mechanism of Action: RNA Synthetase Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: RNA Synthetase Inhibitors
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taro | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 207116-001 | Apr 27, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Encube | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213076-001 | Aug 31, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Padagis Israel | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 212465-001 | Aug 3, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Padagis Israel | MUPIROCIN | mupirocin | OINTMENT;TOPICAL | 065123-001 | Nov 7, 2003 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |